Phase 4
Completed N=9
Cognitive Decline in Non-demented PD
Source: ClinicalTrials.gov NCT01340885 ↗Enrolled (actual)
9
Serious AEs
—
Results posted
Jul 2020
Primary outcomePrimary: Attention Network Effects
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Attention Network Effects |
— | — |
| SECONDARY Quality of Life |
— | — |
| SECONDARY Stroop Color Word Test |
— | — |
| SECONDARY Fatigue |
— | — |
| SECONDARY Depression |
— | — |
| SECONDARY Daytime Sleepiness |
— | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of Parkinson's disease
- Respond to levodopa therapy
Exclusion Criteria
- Dementia
- Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
- Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
- Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
- Currently using any of the study drugs;
- Colorblindness
Data sourced from ClinicalTrials.gov (NCT01340885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.